Clinical trial translation is rapidly changing with AI streamlining traditionally time-intensive workflows. Artificial intelligence enhances human expertise and accelerates the translation of complex clinical content while preserving the linguistic precision and regulatory compliance required in the life sciences industry. This hybrid approach enables faster, more consistent, and scalable translation workflows tailored to the needs of global clinical trials.
AI applications in clinical translation workflows
Machine Translation + Post-Editing (MTPE)
Machine translation engines with life sciences terminology, generate initial drafts which are reviewed by expert linguists to meet regulatory, clinical, and patient-facing standards.
Automated Content Pre-Processing
AI tools extract and structure source content from various file formats, align terminology with pre-approved glossaries, and indicate possible irregularities before translation begins, which reduces human error and improves translation speed.
Translation Memory and Version Control
AI-enhanced translation memory identifies previously translated content across different versions and documents, ensuring reuse of validated language for study phases and in foreign countries.
AI-Assisted Quality Assurance
Automated QA checks scan for formatting, numerical, regulatory compliance and terminology errors, providing an efficient second review alongside human QA.
Benefits of AI-enhanced translation workflows
Speed and Cost Efficiency
Faster turnaround for clinical trial documents, reducing timelines for submissions without compromising on quality.
Multi-Country Consistency
Terminology and translation memory management that is centralised and supported by AI ensures linguistic consistency across various subjects and languages.
High-Volume Trials
From decentralised research to global phase III trials, AI scales translation output efficiently, supporting simultaneous delivery across multiple languages.
Conclusion
In the past, documents that used to take weeks for a group of people to translate and review now take days or hours with less manual input, as AI speeds things up and maintains consistent terminology across foreign countries.
However, AI cannot work alone despite its advancements. Human linguists are still necessary to identify context issues and ensure regulatory compliance. AI is sufficient for drafts and repetitive tasks, so always leave the nuances that could cause problems during submissions for human translation.
Global trials benefit most when they combine both human translation with AI and they save costs by more than half. Humans control accuracy while AI manages the volume and speed. This makes it possible to increase output without compromising on quality or risking regulatory delays, even when launching new pharmaceutical products in different countries simultaneously.
At Biomedica Translations, we specialise in AI-powered translation for clinical trials. Our team uses advanced technology and life sciences expertise to deliver accurate, compliant translations that keep your clinical trials on schedule. We help with planning a multi-country study and streamlining your current workflow to ensure no detail is compromised, from research start-up to final submission.